Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.

Authors

Glenn Hanna

Glenn J. Hanna

Dana-Farber Cancer Institute, Boston, MA

Glenn J. Hanna , Anne M. O'Neill , Vickie Y. Jo , Kristine Wong , Patrick H. Lizotte , Donald J. Annino Jr., Laura A. Goguen , Jason I. Kass , Eleni M. Rettig , Rosh K.V. Sethi , Jochen H. Lorch , Jonathan D. Schoenfeld , Danielle N. Margalit , Roy B. Tishler , Peter C. Everett , Anupam M. Desai , Cloud P. Paweletz , Ann Marie Egloff , Ravindra Uppaluri , Robert I. Haddad

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT03341936

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 6053)

DOI

10.1200/JCO.2021.39.15_suppl.6053

Abstract #

6053

Poster Bd #

Online Only

Abstract Disclosures